Context Therapeutics (Context Therapeutics) Interest Coverage : No Debt ⁽¹⁾ (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Context Therapeutics Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Context Therapeutics's Operating Income for the three months ended in Dec. 2023 was $-6.93 Mil. Context Therapeutics's Interest Expense for the three months ended in Dec. 2023 was $0.00 Mil. Context Therapeutics has no debt. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Context Therapeutics Inc has enough cash to cover all of its debt. Its financial situation is stable.

(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Context Therapeutics's Interest Coverage or its related term are showing as below:

CNTX' s Interest Coverage Range Over the Past 10 Years
Min: No Debt Med: No Debt Max: No Debt
Current: No Debt

CNTX's Interest Coverage is ranked better than
99.41% of 340 companies
in the Biotechnology industry
Industry Median: 138.73 vs CNTX: No Debt

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Context Therapeutics Interest Coverage Historical Data

The historical data trend for Context Therapeutics's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Context Therapeutics Interest Coverage Chart

Context Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Coverage

No Debt

Context Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Coverage	Get a 7-Day Free Trial												No Debt	No Debt	No Debt	No Debt	No Debt

Competitive Comparison of Context Therapeutics's Interest Coverage

For the Biotechnology subindustry, Context Therapeutics's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Context Therapeutics's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Context Therapeutics's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Context Therapeutics's Interest Coverage falls into.

Context Therapeutics Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage

-1

Operating Income

Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt ⁽¹⁾.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Context Therapeutics's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Context Therapeutics's Interest Expense was $0.00 Mil. Its Operating Income was $-25.07 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Context Therapeutics had no debt ⁽¹⁾.

Context Therapeutics's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Here, for the three months ended in Dec. 2023, Context Therapeutics's Interest Expense was $0.00 Mil. Its Operating Income was $-6.93 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Context Therapeutics had no debt ⁽¹⁾.

The higher the ratio, the stronger the company's Financial Strength is.

Context Therapeutics (NAS:CNTX) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

Context Therapeutics Interest Coverage Related Terms

Thank you for viewing the detailed overview of Context Therapeutics's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.

Context Therapeutics (Context Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Context Therapeutics Inc (NAS:CNTX) » Definitions » Interest Coverage

Comparable Companies

Traded in Other Exchanges

6K9:Germany

Address

2001 Market Street, Suite 3915, Unit No. 15, Philadelphia, PA, USA, 19103

Website

https://www.contexttherapeutics.com

Context Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer.

Executives

Martin A. Lehr	director, officer: Chief Executive Officer	3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Jennifer Lynn Minai-azary	officer: Chief Financial Officer	110 MILLER AVENUE, SUITE 100, ANN ARBOR MI 48104
Alex C. Levit	officer: Chief Legal Officer, Corp. Sec	3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Tarek Sahmoud	officer: Chief Medical Officer	3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Richard J Berman	director	305 COLLEGE ROAD EAST, PRINCETON NJ 08540
Jennifer Evans Stacey	director	AUXILIUM PHARMACEUTICALS, INC., 160 WEST GERMANTOWN PIKE, NORRISTOWN PA 19401
Linda West	director	C/O GALERA THERAPEUTICS, INC., 2 W LIBERTY BLVD., #110, MALVERN PA 19355
Evan G. Dick	officer: SVP of R&D	3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
William F. Rencher	officer: Head of CMC and Regulatory	3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Philip W. Kantoff	director	3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104